Publications by authors named "Monika Hubackova"
Article Synopsis
- Metabolic-dysfunction-associated steatotic liver disease (MASLD) is a significant issue tied to obesity, prompting a study on the impact of semaglutide, a medication for weight loss.
- The study involved 16 obese, non-diabetic men over 32 weeks, revealing that semaglutide reduced body weight and liver fat significantly, while dietary changes did not influence these outcomes.
- Notably, changes in liver fat were not linked to weight loss or improved insulin sensitivity, but the treatment did lower certain fatty acids in VLDL-triglycerides, indicating it might reduce liver fat by decreasing new fat production in the liver.
